These activities inhibit the differentiation of exhaustive CD8+ T cells by decreasing expression of both 2B4 (CD244) and PD-1 while increasing IL-2 and CD127 (IL-7Rα receptor) expression on CD8+ T cells in an OT-I melanoma mouse model [111]. Here, RPL17 is linked to melanoma.